Skip to content

Biohaven BHVN Total debt

Total debt at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$7.49M-13.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$10.8M+37.8%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$95.58M-0.5%
uniQure logo
uniQureQURE
$63.32M-4.3%
Eli Lilly logo
Eli LillyLLY
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Plus components not separately reported this period.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's total debt?
Biohaven (BHVN) reported total debt of $286.18M in Q1 2026.
How has Biohaven's total debt changed year-over-year?
Biohaven's total debt increased by 705.9% year-over-year, from $35.51M to $286.18M.
What is the long-term trend for Biohaven's total debt?
Over 4 years (2021 to 2025), Biohaven's total debt has grown at a 206.2% compound annual growth rate (CAGR), from $3.24M to $284.61M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.